by Clinical Cancer Research
The efficacy of chimeric antigen receptor (CAR) T-cell therapy targeting interleukin 13 receptor α2 (IL13Rα2) for patients with malignant gliomas has yet to be determined, but Phase I evidence...
by Transplantation and Cellular Therapy
A retrospective analysis suggests that cellular immunotherapy may offer a survival advantage over pharmacological immunosuppression in the setting of graft-versus-host disease (GVHD) following...
by Blood
Researchers suspect immunosenescence may be implicated when chimeric antigen receptor (CAR) T-cell therapy fails in the setting of chronic lymphocytic leukemia (CLL).
by ACS Applied Materials & Interfaces
Researchers describe a new process that overcomes the limitations of established practices for manufacturing natural killer (NK) cells that express chimeric antigen receptors (CAR).
by ASTCT Talks
In this episode of ASTCT Talks, host Terri Lynn Shigle, PharmD, BCOP, clinical pharmacy specialist with Stem Cell Transplantation and Cellular Therapy Department at The University of Texas MD...
by Yoonhee Choi, MD
In this ASTCT Committee Member Spotlight, Yoonhee Choi, MD, discusses her journey as a hematology-oncology fellow, her research in lymphoid malignancies, and her interest in cellular therapy. She...